Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Pharmorubicin 50mg/25ml inj Cytosafe vials
0801020N0BBAEAE
|
Pharmorubicin | Epirubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Pharmorubicin Rapid Dissolution 10mg inj vials
0801020N0BBAAAA
|
Pharmorubicin | Epirubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Pharmorubicin Rapid Dissolution 20mg inj vials
0801020N0BBABAB
|
Pharmorubicin | Epirubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Pharmorubicin Rapid Dissolution 50mg inj vials
0801020N0BBACAC
|
Pharmorubicin | Epirubicin hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Phasonit LA50 capsules
0206010K0CQABAF
|
Phasonit | Isosorbide mononitrate | Cardiovascular System | No data available |
|
Pheburane 483mg/g granules
0908010P0BDAAAP
|
Pheburane | Sodium phenylbutyrate | Nutrition and Blood | No data available |
|
Phelinun 50mg pdr and solvent for concentrate for inf vials
0801010S0BCAAAD
|
Phelinun | Melphalan | Malignant Disease and Immunosuppression | No data available |
|
Phenindione 50mg tablets
0208020N0AAACAC
|
Phenindione | Phenindione | Cardiovascular System | No data available |
|
Phenobarbital 100mg capsules
0408010N0AAASAS
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 100mg tablets
0408010N0AAAMAM
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 10mg capsules
0408010N0AAA7A7
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 12.5mg/5ml oral liquid
0408010N0AADGDG
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 12.6mg/5ml oral liquid
0408010N0AAEPEP
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 15mg/1ml solution for injection ampoules
0408010P0AAAHAH
|
Phenobarbital sodium | Phenobarbital sodium | Central Nervous System | No data available |
|
Phenobarbital 180mg/5ml oral liquid
0408010N0AAETET
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 18mg/5ml oral liquid
0408010N0AAEHEH
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 2.5mg/5ml oral liquid
0408010N0AAEQEQ
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 200mg/5ml oral liquid
0408010N0AACMCM
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 21mg/5ml oral liquid
0408010N0AAEDED
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 225mg/5ml oral liquid
0408010N0AADFDF
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 247.5mg/5ml oral liquid
0408010N0AAEFEF
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 25mg capsules
0408010N0AAAZAZ
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 25mg/5ml oral solution
0408010N0AAEVEV
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 28.5mg/5ml oral liquid
0408010N0AADXDX
|
Phenobarbital | Phenobarbital | Central Nervous System | No data available |
|
Phenobarbital 30mg/1ml solution for injection ampoules
0408010P0AAAIAI
|
Phenobarbital sodium | Phenobarbital sodium | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.